Amneal Pharmaceuticals (AMRX) Intangibles (2017 - 2026)

Amneal Pharmaceuticals has reported Intangibles for 10 years, with the latest figure at $587.8 million in Q2 2026.

• On a quarterly basis, Intangibles fell 9.5% year-over-year to $587.8 million in Q2 2026; TTM through Jun 2026 was $587.8 million, a 9.5% decrease from a year earlier, with the FY2025 full-year figure at $563.5 million, down 23.06% from the prior year.
• Intangibles was $587.8 million for Q2 2026 at Amneal Pharmaceuticals, up from $534.9 million in the prior quarter.
• The five-year high for Intangibles was $1.2 billion in Q1 2022, with the low at $534.9 million in Q1 2026.
• Average Intangibles over 5 years is $856.5 million, with a median of $839.6 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2025: Intangibles dropped 4.21% in 2022, then retreated 24.64% in 2025.
• Over 5 years, Intangibles stood at $1.1 billion in 2022, then fell by 18.76% to $890.4 million in 2023, then slipped by 17.75% to $732.4 million in 2024, then declined by 23.06% to $563.5 million in 2025, then gained by 4.32% to $587.8 million in 2026.
• The last three Intangibles figures came in at $587.8 million (Q2 2026), $534.9 million (Q1 2026), and $563.5 million (Q4 2025), per Business Quant data.